According to a mouse model study of MS, the GLP-1 agonist NLY01 delayed the onset and decreased the severity of experimental autoimmune encephalomyelitis (p ≤ 0.0001) [19]. The gene discussed is GLP1R; the disease is myeloid sarcoma.